Compare · UNH vs YDES
UNH vs YDES
Side-by-side comparison of UnitedHealth Group Incorporated (UNH) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both UNH and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $304.51B, about 890.1x YDES ($342.1M).
- Over the past year, UNH is up 6.3% and YDES is down 42.8% - UNH leads by 49.1 points.
- UNH has been more active in the news (17 items in the past 4 weeks vs 1 for YDES).
- UNH has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- UnitedHealth Group Incorporated
- YD Bio Limited
- Price
- $340.03+2.93%
- $4.78+4.71%
- Market cap
- $304.51B
- $342.1M
- 1M return
- -19.97%
- +8.64%
- 1Y return
- +6.32%
- -42.75%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 1
- Recent ratings
- 25
- 0
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest UNH
- UnitedHealth upgraded by TD Cowen with a new price target
- CMS Proposes Medicare Advantage Audit Recoveries Reaching Back to 2018
- Before the Bell: Rate-Hike Signals, Health Insurer Losses and Cyber Gains
- UnitedHealthcare and CPESN Announce New Care Delivery Model Expanding Access to Care in Rural and Underserved Communities Through Independent Pharmacies
- Chief Executive Officer, UHC Noel Timothy John covered exercise/tax liability with 587 shares, decreasing direct ownership by 3% to 17,148 units (SEC Form 4)
- New insider Bell Madeline S. claimed no ownership of stock in the company (SEC Form 3)
- UnitedHealth Group Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Madeline Bell Joins UnitedHealth Group Board of Directors
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- UnitedHealth Group Board Authorizes Payment of Quarterly Dividend
Latest YDES
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
- SEC Form 4 filed by YD Bio Limited
- SEC Form 4 filed by YD Bio Limited
- YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
- CEO Shen Ethan Phd bought $48,895 worth of Ordinary Shares (12,700 units at $3.85), increasing direct ownership by 0.11% to 11,258,331 units (SEC Form 4)
- CEO Shen Ethan Phd bought $12,183 worth of Ordinary Shares (3,100 units at $3.93), increasing direct ownership by 0.03% to 11,245,631 units (SEC Form 4)
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute